Vakilian Alireza, Khorramdelazad Hossein, Heidari Parisa, Sheikh Rezaei Zahra, Hassanshahi Gholamhossein
Geriatric Care Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Molecular Medicine Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Neurochem Int. 2017 Feb;103:1-7. doi: 10.1016/j.neuint.2016.12.013. Epub 2016 Dec 24.
Glioblastoma multiform (GBM) is described as one of the most frequent primary brain tumors. These types of malignancies constitute only 15% of all primary brain tumors. Despite, extensive developments on effective therapeutic methods during the 20th century as well as the first decade of the present century (21st), the median survival rate for patients suffering from GBM is only approximately 15 months, even in response to multi-modal therapy. numerous types of reticuloendothelial system cells such as macrophages and microglial cells occupied within both GBM and also normal surrounding tissues. These immune cells acquire an otherwise activated phenotype with potent tumor-tropic functions that contribute to the glioma growth and invasion. The CC chemokine, CCL2 (previously named MCP-1) is of the most important CC chemokines family member involving in regulation of oriented migration and penetrative infiltration of mainly reticuloendothelial system cells specifically monocyte/macrophage phenotypes. Fundamental parts are played by CCL2 and its related receptor (the CCR2) in brain tumors and obviously in migration of monocytes from the bloodstream through the vascular endothelium. Therefore, CCL2/CCR2 axis is required for the routine immunological surveillance of tissues, in accordance with response to inflammation. Briefly, in this review, we have tried our best to collect the latest, straightened and summarize literature reports exist within data base regarding the interaction between microglia/macrophages and CCL2/CCR2 axis in GBM. We aimed to discuss potential application of this chemokine/receptor interaction axis for the expansion of future anti-glioma therapies as well.
多形性胶质母细胞瘤（GBM）被认为是最常见的原发性脑肿瘤之一。这类恶性肿瘤仅占所有原发性脑肿瘤的15%。尽管在20世纪以及本世纪（21世纪）的第一个十年里，有效治疗方法有了广泛的发展，但GBM患者的中位生存期即使在接受多模式治疗的情况下也仅约为15个月。在GBM及其周围正常组织中存在多种类型的网状内皮系统细胞，如巨噬细胞和小胶质细胞。这些免疫细胞获得了具有强大肿瘤趋向性功能的活化表型，促进了胶质瘤的生长和侵袭。CC趋化因子CCL2（以前称为MCP-1）是CC趋化因子家族中最重要的成员之一，主要参与调节网状内皮系统细胞特别是单核细胞/巨噬细胞表型的定向迁移和穿透性浸润。CCL2及其相关受体（CCR2）在脑肿瘤中，尤其是在单核细胞从血液中穿过血管内皮的迁移过程中发挥着重要作用。因此，CCL2/CCR2轴对于组织的常规免疫监视以及对炎症的反应是必需的。简而言之，在本综述中，我们尽力收集了数据库中有关小胶质细胞/巨噬细胞与GBM中CCL2/CCR2轴之间相互作用的最新、整理和总结的文献报告。我们旨在讨论这种趋化因子/受体相互作用轴在未来抗胶质瘤治疗扩展中的潜在应用。
